NCT05486468View on ClinicalTrials.gov

The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment

PHASE3RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 5, 2022

Primary Completion Date

July 31, 2026

Study Completion Date

December 31, 2026

Conditions
UveitisUveitis, PosteriorUveitis, AnteriorUveitis, Intermediate
Interventions
DRUG

Yutiq 0.18 MG Drug Implant

YUTIQ ® (fluocinolone acetonide intravitreal implant) 0.18 mg, for intravitreal injection

OTHER

Sham Injection

Sham injection

Trial Locations (1)

75075

RECRUITING

Texas Retina Associates, Plano

Sponsors
All Listed Sponsors
collaborator

Eye Point Pharmaceuticals

UNKNOWN

collaborator

ANI Pharmaceuticals

INDUSTRY

lead

Texas Retina Associates

OTHER

NCT05486468 - The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment | Biotech Hunter | Biotech Hunter